Reprieve is a medical technology company developing a diuretic treatment device for acute decompensated heart failure (ADHF) patients.
reprievecardio.com
Milford, MA
CEO: Mark Pacyna
Arboretum Lead: Jan Garfinkle
Reprieve Cardiovascular
IN THE NEWS
Reprieve Cardiovascular Secures $61 Million Financing and Enrolls First Patient in Pivotal Study
Reprieve Cardiovascular, Inc., a clinical-stage company pioneering intelligent decongestion management therapy for acute decompensated heart failure (ADHF), today announced the close of an oversubscribed $61 million Series B financing led…
Read More
Reprieve Cardiovascular Builds Clinical Momentum with Positive Results from FASTR Pilot Trial
Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced topline results from its FASTR randomized pilot study, evaluating the Reprieve System for…
Read More
First-In-Human Study Demonstrates the Potential of the Reprieve System in Patients with Acute Decompensated Heart Failure
Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced the first-in-human results of the Reprieve System at the CSI Focus D-HF (Device…
Read More
